Background: COVID-19 disease is a global phenomenon that is exerting its influence on a lot more than just health sector. Colleges, Institutes, and Schools were also part of the lockdown that followed the outbreak. Educational institutes have shifted from classroom teaching to online teaching-learning platforms.
Aim: The study aimed to assess teachers' and students' experiences on online teaching during the COVID-19 pandemic at university dental teaching hospital Pune, India.
Methodology: The study design was a cross-sectional questionnaire-based study. The research setting was online. Eligibility Criteria of the study were the teaching staff of the College who had taken to online teaching and undergraduate students who had attended online classes. Custom-made questionnaire link using 'Google form' was sent to teachers and students through WhatsApp and E-mail.
Results: 63% of students and 90% of staff responded with the questionnaires. During COVID-19, 96.7% of teachers and 98.4% of students had used Zoom as an online teaching platform. 25.6% of teachers had experienced network issues as the main problem. 90% of staff did not prefer online teaching over classroom teaching. 10% of teachers did prefer online teaching during the COVID-19 pandemic. 82.4% of students didn't prefer an online learning method. The most common difficulties faced by students were network issues.
Conclusion: Knowledge of teachers' and students' experiences on online teaching is important to overcome the issues faced by them. Teachers' opinions are vital for improvising and dealing with issues with online teaching. The result of this study can be used as a guide for improving effective online teaching.
Introduction Mucormycosis emerged as a wildfire in post-covid-19 infected patients. Most frequently involved sites of mucormycosis are rhino-orbital, rhino-sinusal and rhino-orbito-cerebral. The hallmark sign of mucormycosis is tissue necrosis, which is often a late sign. The fatality rate of mucormycosis is 46% globally. Despite early aggressive combined surgical and medical therapy, the prognosis of mucormycosis is poor. Methods We searched the electronic database of PubMed, web of science, Embase, Scopus and Google Scholar from Jan 2020 until December 2021 using keywords. We retrieved all the granular details of original research articles, case reports/series of patients with rhino-orbito-cerebral mucormycosis (ROCM), and COVID-19 reported worldwide. Subsequently, we analyzed the patient characteristics, associated comorbidities, location of mucormycosis, treatment given and its outcome in people with COVID-19. (Prospero registration-CRD42021256830, June 4, 2021).Results Overall, 544 rhino-orbito-cerebral mucormycosis patients were included in our review with a history of Covid-19 infection. Out of which 410 patients had diabetes mellitus which has proven to be major contributing immunocompromised disease. Other diseases like hypertension, chronic kidney diseases, hypothyroidism, etc., were also attributed as an immunocompromised disease causing increased number of covid associated mucormycosis cases. We found out that total number of patients alive after taking only antifungal drug treatment were 25 in number, whereas total number of patients alive when antifungal drugs were combined with surgical intervention were 428 which was significantly higher. Conclusion Our systematic review concluded that surgical debridement should be performed whenever feasible in parallel to antifungal treatment in order to reduce the mortality rate of COVID-19 associated rhino-orbito-cerebral mucormycosis patients.
KeywordsRhino-orbito-cerebral mucormycosis • Covid associated rhino-orbito-cerebral mucormycosis • Covid associated mucormycosis • Mortality • Treatment * Sneha Setiya
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.